PL2395990T3 - Materiał leczniczy i sposoby leczenia zaburzeń rozwojowych, w tym autyzmu współistniejącego i autyzmu idiopatycznego - Google Patents
Materiał leczniczy i sposoby leczenia zaburzeń rozwojowych, w tym autyzmu współistniejącego i autyzmu idiopatycznegoInfo
- Publication number
- PL2395990T3 PL2395990T3 PL10705949T PL10705949T PL2395990T3 PL 2395990 T3 PL2395990 T3 PL 2395990T3 PL 10705949 T PL10705949 T PL 10705949T PL 10705949 T PL10705949 T PL 10705949T PL 2395990 T3 PL2395990 T3 PL 2395990T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- disorders including
- developmental disorders
- treating developmental
- idiopathic autism
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15185809P | 2009-02-12 | 2009-02-12 | |
| PCT/US2010/024008 WO2010093859A1 (en) | 2009-02-12 | 2010-02-12 | Material and methods for treating developmental disorders including comorbid and idiopathic autism |
| EP10705949.5A EP2395990B1 (en) | 2009-02-12 | 2010-02-12 | Material and methods for treating developmental disorders including comorbid and idiopathic autism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2395990T3 true PL2395990T3 (pl) | 2015-04-30 |
Family
ID=42103866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10705949T PL2395990T3 (pl) | 2009-02-12 | 2010-02-12 | Materiał leczniczy i sposoby leczenia zaburzeń rozwojowych, w tym autyzmu współistniejącego i autyzmu idiopatycznego |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9463172B2 (pl) |
| EP (1) | EP2395990B1 (pl) |
| JP (1) | JP5688035B2 (pl) |
| AU (1) | AU2010213683B2 (pl) |
| CA (1) | CA2781830C (pl) |
| DK (1) | DK2395990T3 (pl) |
| ES (1) | ES2530047T3 (pl) |
| HR (1) | HRP20150120T1 (pl) |
| PL (1) | PL2395990T3 (pl) |
| PT (1) | PT2395990E (pl) |
| SI (1) | SI2395990T1 (pl) |
| WO (1) | WO2010093859A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011150380A1 (en) * | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| US20130296430A1 (en) * | 2012-05-03 | 2013-11-07 | Antonio Hardan | Compositions and methods for treating autism and autism spectrum disorder |
| WO2014018468A1 (en) * | 2012-07-22 | 2014-01-30 | Indiana University Research And Technology Corporation | Modulation sapp, sapp alpha and bdnf levels in individuals diagnosed with fxs and asd |
| EP3003297A4 (en) * | 2013-06-05 | 2017-04-19 | Synchroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| PL3058371T3 (pl) * | 2013-10-14 | 2021-11-08 | Indiana University Research And Technology Corporation | Zastosowanie akamprozatu do modulowania aktywacji erk 1-2 w modelach zwierzęcych dla fxs i asd oraz u osób z rozpoznaniem fxs i asd |
| CN107636466B (zh) | 2015-02-18 | 2020-07-21 | 阿斯顿大学 | 先兆子痫的诊断性测定和治疗 |
| IL255343B1 (en) | 2015-05-04 | 2024-06-01 | Confluence Pharmaceuticals Llc | Essay formulations of acamprosate |
| JP2018526345A (ja) * | 2015-08-04 | 2018-09-13 | コンフルーエンス ファーマシューティカルズ，エルエルシー | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602150A (en) | 1992-10-02 | 1997-02-11 | Research Foundation For Mental Hygiene, Inc. | Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| JP2005500260A (ja) * | 2001-04-02 | 2005-01-06 | ブラウン ユニバーシティ リサーチ ファウンデイション | ｍＧｌｕＲ５アンタゴニストの組成物および使用方法 |
| US6916821B2 (en) | 2001-04-02 | 2005-07-12 | Brown University | Methods of treating disorders with Group I mGluR antagonists |
| DE10129265A1 (de) | 2001-06-18 | 2003-01-02 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
| US20040102525A1 (en) | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
| EP2982372B1 (en) | 2005-04-05 | 2020-08-05 | Yale University | Glutamate modulating agents in the treatment of mental disorders |
| JP2010510314A (ja) | 2006-11-22 | 2010-04-02 | シーサイド セラピューティクス，エルエルシー | 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法 |
| US20080171750A1 (en) * | 2007-01-11 | 2008-07-17 | Braincells, Inc. | Modulation Of Neurogenesis With Use of Modafinil |
| US20100317715A1 (en) | 2007-12-21 | 2010-12-16 | Vollrath Benedikt | Methods for treating neuropsychiatric conditions |
-
2010
- 2010-02-12 PT PT107059495T patent/PT2395990E/pt unknown
- 2010-02-12 JP JP2011550249A patent/JP5688035B2/ja active Active
- 2010-02-12 US US13/201,014 patent/US9463172B2/en active Active
- 2010-02-12 EP EP10705949.5A patent/EP2395990B1/en active Active
- 2010-02-12 WO PCT/US2010/024008 patent/WO2010093859A1/en active Application Filing
- 2010-02-12 AU AU2010213683A patent/AU2010213683B2/en active Active
- 2010-02-12 ES ES10705949.5T patent/ES2530047T3/es active Active
- 2010-02-12 DK DK10705949.5T patent/DK2395990T3/en active
- 2010-02-12 PL PL10705949T patent/PL2395990T3/pl unknown
- 2010-02-12 SI SI201030861T patent/SI2395990T1/sl unknown
- 2010-02-12 CA CA2781830A patent/CA2781830C/en active Active
-
2015
- 2015-02-02 HR HRP20150120TT patent/HRP20150120T1/hr unknown
-
2016
- 2016-06-24 US US15/192,535 patent/US9956189B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2395990T3 (en) | 2015-02-23 |
| CA2781830C (en) | 2018-03-27 |
| EP2395990B1 (en) | 2015-01-07 |
| SI2395990T1 (sl) | 2015-04-30 |
| US9463172B2 (en) | 2016-10-11 |
| PT2395990E (pt) | 2015-02-09 |
| AU2010213683A1 (en) | 2011-09-01 |
| US20160303057A1 (en) | 2016-10-20 |
| CA2781830A1 (en) | 2010-08-19 |
| AU2010213683B2 (en) | 2016-04-21 |
| EP2395990A1 (en) | 2011-12-21 |
| JP5688035B2 (ja) | 2015-03-25 |
| JP2012517480A (ja) | 2012-08-02 |
| HRP20150120T1 (hr) | 2015-05-08 |
| US20120016036A1 (en) | 2012-01-19 |
| WO2010093859A1 (en) | 2010-08-19 |
| ES2530047T3 (es) | 2015-02-26 |
| US9956189B2 (en) | 2018-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1207651A1 (en) | Material and methods for treating or preventing her-3 associated diseases her-3 | |
| EP2521724A4 (en) | ACTIVE AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | |
| EP2766483A4 (en) | METHOD AND COMPOSITIONS FOR SCREENING AND TREATING DEVELOPMENT DISORDERS | |
| HK1174064A1 (zh) | 用於細胞增殖相關的疾病的方法和組合物 | |
| EP2406389A4 (en) | METHOD AND COMPOSITIONS FOR CELL-RETENTION-BASED DISEASES | |
| EP2424448A4 (en) | DEVICES AND METHODS FOR TREATING A PAIN ASSOCIATED WITH AMYGDALECTOMIES | |
| IL215455A0 (en) | Methods and materials for delivering molecules | |
| ZA201303423B (en) | Compositions and methods for treating myelofibrosis | |
| EP2416657A4 (en) | COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF | |
| IL209216A0 (en) | Methods for preventing and treating neurodegenerative diseases | |
| PL2395990T3 (pl) | Materiał leczniczy i sposoby leczenia zaburzeń rozwojowych, w tym autyzmu współistniejącego i autyzmu idiopatycznego | |
| EP2504428A4 (en) | METHOD AND COMPOSITIONS FOR TREATING OXALATE-MEDIATED SUFFERING | |
| GB0903299D0 (en) | Composition and methods | |
| GB0912468D0 (en) | Composition and method | |
| HK1171379A1 (en) | Composition for improving brain function and method for improving brain function | |
| EP2340254A4 (en) | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY | |
| EP2237777A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES | |
| EP2654899A4 (en) | METHODS OF TREATING NEUROLOGICAL CONDITIONS AND COMPOSITIONS AND PRODUCTS USED THEREFOR | |
| HK1154308A1 (en) | Transistor and method thereof | |
| EP2448458A4 (en) | SYSTEM AND METHODS FOR WIPING MATERIAL | |
| EP2427052A4 (en) | METHODS AND COMPOSITIONS FOR USE IN THE TREATMENT OF OPHTHALMIC DISORDERS | |
| GB0901667D0 (en) | Composition and method | |
| EP2278982A4 (en) | COMPOSITIONS AND METHODS OF TREATING NEURODEEGENERATIVE ILLNESSES | |
| GB0912714D0 (en) | Composition and process | |
| GB201021822D0 (en) | Cleaning composition and method |